today it looks like the shorts are adding to their positions right now, however, lets for fun see what it closes for the week. Cheers to all the LONGS
next year legal will drop as hiring continues to grow along with R&D. What does that tell you? KABOOM
Yeah get outta here your trashing my board bruh
then go to that board
moving on up today, nearly $10 now
Revenue of $66.5 million is higher than analyst expectation of $64.6 million.
Painkiller Subsys accounts for $66.1 million of the revenue.
Fourth quarter expenses climb as legal costs rise and research and development spending goes up.
they are just holding and hoping for this stock will drop. This may sequentially be up 2-4% a day for a while due to small portions of the short sellers covering their #$%$. 5 drugs in phase 3 clinical trials... Jackpot
Correct me if I'm wrong but your question is a little confusing. Pain killers are already regulated by the FDA/DEA based on their relative value of therapeutic use and potential for addiction. Hydrocodone, oxycotin and other synthetic opioids are already regulated, this is while they are not sold over the counter and need the prescription of a licensed MD or DO. So in short, high strength pain killers like synthetic opioids and Subsys are already regulated.
and the voices of all of those sales reps they recently hired and will continue doing so this year. Does that sound like a company in trouble? Giving me shivers!
Sentiment: Strong Buy